Table 2.
Maintenance regimens and reasons for stopping maintenance therapy.
| Maintenance < 3 Years (n = 102) |
Maintenance ≥ 3 Years (n = 238) |
|||
|---|---|---|---|---|
| Maintenance Drugs | n | % | n | % |
| Lenalidomide | 90 | 88.2 | 214 | 89.9 |
| Bortezomib | 15 | 14.7 | 21 | 8.8 |
| Ixazomib | 0 | 0 | 12 | 5.0 |
| Lenalidomide + Bortezomib | 0 | 0 | 2 | 0.8 |
| Lenalidomide + Cyclophosphamide | 0 | 0 | 2 | 0.8 |
| Pomalidomide | 0 | 0 | 3 | 1.3 |
| Pomalidomide + Cyclophosphamide | 0 | 0 | 1 | 0.4 |
| Thalidomide | 3 | 2.9 | 1 | 0.4 |
| Prednisone | 3 | 2.9 | 1 | 0.4 |
| Reasons for stopping * | ||||
| Patient Preference | 23 | 22.5 | 7 | 2.9 |
| Physician Decision | 1 | 1 | 0 | 0 |
| Progression | 0 | 0 | 57 | 23.9 |
| Recurrent Infection | 1 | 1 | 0 | 0 |
| SPM | 4 | 3.9 | 5 | 2.1 |
| Adverse events | 51 | 50 | 30 | 12.6 |
| Other | 22 | 21.6 | 8 | 3.4 |
* 131 patients in maintenance ≥ 3 years group were still on maintenance at last follow up.